Survival outcomes in phase I trial combining VCN-01 and durvalumab (MEDI4736) in subjects with recurrent/ metastatic head and neck squamous cell carcinoma refractory to previous immunotherapy treatment

被引：0

作者：

Jove, M. ^{[1
]}

Brana, I. ^{[2
,3
]}

Oliva Bernal, M. ^{[4
]}

Hernando Calvo, A.

Erasun Lecuona, C. ^{[4
]}

Assaf Pastrana, J. D. ^{[2
,3
]}

Mato-Berciano, A. ^{[5
]}

V. Maliandi, M. ^{[5
]}

Torres-Manjon, S. ^{[6
]}

Moreno, R. ^{[6
]}

Le, C. ^{[7
]}

G. Nuciforo, P. ^{[8
]}

Alemany, R. ^{[6
]}

Capella, G. ^{[9
]}

Blasco, C. ^{[10
]}

Cascallo Piqueras, M. ^{[10
]}

Mesia Nin, R. ^{[11
]}

机构：

[1] Catalan Inst Oncol ICO, Med Oncol Phase Funct Unit 1, Lhospitalet De Llobregat, Spain

[2] Vall dHebron Hosp Univ, Med Oncol Dept, Barcelona, Spain

[3] Vall dHebron Inst Oncol VHIO, Barcelona, Spain

[4] Catalan Inst Oncol ICO, Med Oncol Phase Funct Unit 1, Barcelona, Spain

[5] Theriva Biol, R&D, Parets Del Valles, Spain

[6] ICO Inst Catala Oncol Hosp Duran I Reynals, IDIBELL, ProCure Program ICO Program Mol Mech & Expt Ther, Lhospitalet De Llobregat, Spain

[7] Theriva Biol, Stat & Analyt, Rockville, MD USA

[8] Vall dHebron Inst Oncol VHIO Cellex Ctr, Mol Oncol Dept, Barcelona, Spain

[9] IDIBELL, Program Mol Mech & Expt Therapy Oncol Oncobell, Lhospitalet De Llobregat, Spain

[10] Theriva Biol, Clin Operat, Parets Del Valles, Spain

[11] IGTP, ICO Inst Catala Oncol, Med Oncol Dept, B ARGO Grp, Badalona, Spain

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.2081

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

937P

引用

页码：S589 / S590

页数：2

共 50 条

[1] Survival outcomes in phase I trial combining VCN-01 and durvalumab (MEDI4736) in subjects with recurrent/metastatic head and neck squamous cell carcinoma refractory to previous immunotherapy treatment
Jove, M.
Brana, I.
Oliva Bernal, M.
Hernando Calvo, A.
Erasun Lecuona, C.
Assaf Pastrana, J. D.
Mato-Berciano, A.
Maliandi, M. V.
Torres-Manjon, S.
Moreno, R.
Le, C.
Nuciforo, P. G.
Alemany, R.
Capella, G.
Blasco, C.
Cascallo Piqueras, M.
Mesia Nin, R.
ANNALS OF ONCOLOGY, 2023, 34 : S589 - S589
[2] Phase I study to evaluate the safety, tolerability, and efficacy of VCN-01 in combination with durvalumab (MEDI4736) in subjects with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC)
Jove, M.
Brana, I.
Oliva Bernal, M.
Hernando-Calvo, A.
Erasun Lecuona, C.
Assaf Pastrana, J. D.
Bazan Peregrino, M.
Mato-Berciano, A.
Maliandi, M. V.
Torres-Manjon, S.
Martinez De Villareal, J.
Real, F. X.
Nuciforo, P. G.
Alemany, R.
Capella, G.
Blasi, E.
Blasco, C.
Cascallo Piqueras, M.
Mesia Nin, R.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1112 - S1112
[3] VCN-01 plus durvalumab in subjects with recurrent/metastatic head & neck squamous cell carcinoma (R/M HNSCC): Phase I clinical trial
Jove, M.
Brana, I.
Taberna, M.
Hernando-Calvo, A.
Brenes Castro, J.
Garralda, E.
Plana Serrahima, M.
Manos Pujol, M.
Capella, G.
Alemany, R.
Blasi, E.
Blasco, C.
Cascallo Piqueras, M.
Nin, R. Mesia
ANNALS OF ONCOLOGY, 2019, 30 : 47 - 47
[4] Immune alterations in a window of opportunity for durvalumab (MEDI4736) plus metformin trial in squamous cell carcinoma of the head and neck (SCCHN)
Curry, J. M.
Nwagu, U.
Harshyne, L., Jr.
Linnenbach, A.
Srivastava, N.
Cognetti, D. M.
Luginbuhl, A.
Zinner, R.
Axelrod, R.
Bar-Ad, V.
Goldman, R. A.
Rodeck, U.
Martinez-Outschoorn, U.
Johnson, J. M.
Argiris, A.
ANNALS OF ONCOLOGY, 2020, 31 : S665 - S666
[5] Window of opportunity for durvalumab (MEDI4736) plus metformin trial in squamous cell carcinoma of the head and neck (SCCHN): Interim safety analysis
Richa, T.
Johnson, M.
Cognetti, D. M.
Argiris, A.
Luginbuhl, A.
Zinner, R.
Axelrod, R.
Bar-Ad, V.
Goldman, R.
Rodeck, U.
Martinez-Outschoorn, U.
Curry, J. M.
ANNALS OF ONCOLOGY, 2019, 30
[6] Phase I study to evaluate the safety and efficacy of MEDI4736 in combination with tremelimumab in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN).
Siu, Lillian L.
Papadopoulos, Kyriakos P.
Tsai, Frank Yung-Chin
Hansen, Aaron Richard
Robbins, Paul B.
Li, Xia
Lai, Dominic W.
Blake-Haskins, John A.
Fury, Matthew G.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[7] Spatial distribution of CD8+and FoxP3+in a window of opportunity for durvalumab (MEDI4736) plus metformin trial in squamous cell carcinoma of the head and neck (HNSCC)
Curry, J. M.
Alnemri, A.
Sussman, S.
Harshyne, L.
Linnenbach, A.
Stapp, R.
South, A.
Nwagu, U.
Swendseid, B.
Tuluc, M.
Gargano, S.
Cognetti, D.
Bar-Ad, V.
Luginbuhl, A.
Axelrod, R.
Whitaker-Menezes, D.
Mahoney, M. G.
Argiris, A.
Martinez-Outschoorn, U.
Johnson, J. M.
ANNALS OF ONCOLOGY, 2021, 32 : S787 - S787
[8] Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Wildsmith, Sophie
Li, Weimin
Wu, Song
Stewart, Ross
Morsli, Nassim
Raja, Rajiv
Zhang, Qu
Ye, Jiabu
He, Philip
Shetty, Jagdish
Yovine, Alejandro
Holoweckyj, Nicholas
Real, Katia
Walker, Jill
Wrona, Magdalena
de los Reyes, Melissa
Barker, Craig
Whiteley, Jessica
Haddad, Robert
Licitra, Lisa
Ferris, Robert
Fayette, Jerome
Zandberg, Dan P.
Siu, Lillian L.
Mesia, Ricard
CLINICAL CANCER RESEARCH, 2023, 29 (11) : 2066 - 2074
[9] Phase 3 study of durvalumab (MEDI4736) alone or in combination with tremelimumab versus standard of care (SoC) in platinum-resistant recurrent ormetastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): EAGLE
Licitra, L.
Even, C.
Haddad, R.
Tahara, M.
Goswami, T.
Franks, A.
Emeribe, U.
Jarkowski, A., III
Melillo, G.
Ferris, R. L.
ANNALS OF ONCOLOGY, 2015, 26 : 101 - 101
[10] Phase II Trial of Combined Durvalumab Plus Tremelimumab with Proton Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Kim, Hana
Park, Sehhoon
Jung, Hyun Ae
Lee, Se-Hoon
Park, Keunchil
Ahn, Yong Chan
Oh, Dongryul
Ahn, Myung-Ju
CANCER RESEARCH AND TREATMENT, 2023, 55 (04): : 1104 - 1112

← 1 2 3 4 5 →